Background {#Sec1}
==========

Neoadjuvant chemotherapy (NACT) is a standard part of the multidisciplinary treatment of breast cancer \[[@CR1]\]. Nowadays up to 30% of all breast cancer patients receive NACT \[[@CR2]\]. NACT has been shown to be equivalent to adjuvant chemotherapy in terms of disease free, distant disease-free, and overall survival in several clinical trials and enables more breast cancer patients to receive breast-conserving therapy \[[@CR3]--[@CR6]\]. Depending on the biological subtype of the tumor, up to 60% of the patients achieve a pathological complete response in the breast (bpCR) \[[@CR7], [@CR8]\]. The most conservative definition of a bpCR was found to be a complete disappearance of invasive and in situ residual tumor disease in the breast (ypT0) \[[@CR9]--[@CR11]\].

Achieving a bpCR is a predictor for an improved disease free and overall survival, and it is used as a surrogate clinical endpoint for long term outcome \[[@CR1], [@CR4], [@CR6], [@CR10]--[@CR16]\]. Only mediocre diagnostic accuracy can be reached when predicting a bpCR before surgery by a combination of multiple aspects such as tumor biology, the applied NACT regimen, and breast imaging results \[[@CR8], [@CR17]--[@CR20]\].

Due to this diagnostic uncertainty, surgery after NACT is considered to be obligatory for all patients in order to either completely remove residual disease in non-bpCR cases or to diagnose a bpCR \[[@CR21]\]. So far, surgery is the only valid diagnostic instrument to diagnose a bpCR. However, there is evidence that in cases of a shrinking tumor a less radical breast surgery is oncologically safe. \[[@CR22]\]. The case of a clinical or imaging complete response (cCR), however, requires the diagnostic resection of (parts of) the initial tumor bed in order to confirm (or not) a possible bpCR histologically \[[@CR6], [@CR23]\].

Methods/design {#Sec2}
==============

Aims {#Sec3}
----

The main purpose of this trial is to evaluate the accuracy of a vacuum-assisted biopsy (VAB) for a reliable diagnosis of a bpCR after NACT. The study is designed to prove the false negative rate of the VAB is below 10% (= sensitivity is 90% or above).

Design {#Sec4}
------

This study is designed as a multicenter, confirmative, one-armed, intra-individually-controlled, open, diagnostic trial. Patients will be recruited in 21 centers in Germany.

Participants {#Sec5}
------------

Participants are female patients aged 18 years and older with primary breast cancer after NACT treatment which has been performed for at least 12 weeks and resulted in cPR or cCR (see below). Patients can be enrolled if the following inclusion criteria are met: any cT and cN stage, except cT4 stages; patient is scheduled to undergo any routine breast cancer surgical intervention planned according to guidelines (breast conservation or mastectomy); the residual intramammary target lesion or clip marker is visible in mammography and / or ultrasound; diagnosis of imaging complete or partial response according to RECIST 1.1 by mammography or ultrasound, according to local routine; in case of multicentric disease: confirmation of the same tumorbiological subtype of tumor defined by immunohistology in at least 2 lesions. Only one breast per patient will be included, in bilateral cancer one breast can be included. Patients have to be able to understand the character and individual consequences of the clinical trial and must give written informed consent before enrollment in the trial. Patients will be excluded from the trial in case of palliative or recurrent breast cancer. Further exclusion criteria are dislocation of clip marker (\> 5 mm distance to the initial target lesion border at the time of clip placement), contraindication for VAB or associated procedures (e.g. local anesthesia) as well as pregnancy and lactation.

Intervention {#Sec6}
------------

In this study design the control (breast surgery = reference test) and the comparator (VAB = index test) will both be performed on every patient. After an initial screening visit (visit 1), during which inclusion criteria will be checked and informed consent will be obtained, the VAB will be performed (visit 2). This intervention visit may vary by patient, tumor, and trial site characteristics and may either be an ultrasound guided or a stereotactically guided VAB. In analogy to the German S3 guideline on primary breast cancer management, we recommend to take at least 12 biopsies with 10G needles or less in case of larger needle sizes \[[@CR24]\], bearing in mind that the probability of a sampling error might be reduced by taking more samples. As quantification of the specimen is not easily possible during the VAB (weight, as well as the number of biopsies taken does not necessarily quantify the amount of adequate tissue), we propose to take as many samples as reasonably justifiable (according to the local investigator). The VAB will be performed according to standards in primary breast diagnostics and according to the above mentioned guidelines. The intervention may be performed before surgery at a separate visit, the day before surgery (e. g. during the wire location), or in the operation room immediately prior to surgery depending on the site specific organizational setting. As the surgery will be performed according to clinical routine, there is no specific time frame for each trial visit. The physician performing the biopsy will be asked to quantify subjectively the level of representativeness of the biopsy (secondary outcome measure). The imaging performed during VAB may not be used for assessment of inclusion/exclusion criteria. Specimen radiography may be applied as an optional procedure after VAB to assess the representativeness of the specimen radiologically (secondary outcome measure). Standard surgery is regarded as the third trial visit (visit 3) as standard surgical excision (either breast conserving surgery or mastectomy) is the reference test. Adverse events will be documented until the end of visit 3.

Adverse events {#Sec7}
--------------

Possible adverse events of the VAB procedure may occur while the biopsy is taken. Due to the simple study design following clinical routine, very few adverse events are expected. Within the pilot study \[[@CR25]\] there were no safety issues. As the biopsy is an additional minimal invasive intervention, it is accompanied by a number of possible risks. Those include bleeding with (1) hematoma and (2) possible urgent surgical intervention, infection, and injuries of surrounding tissue. Theoretically, VAB could challenge the surgeon, e. g. due to a hematoma and may lead to limitations in reliably assessing (3) the final tumor size or (4) the resection margins by pathology. The first two are informative but not critical; the latter situations are also possible even without preoperative VAB but should not exceed 10% of the patients (ypTx \</= 10% and final R1 / Rx status \</= 10%). We propose to interrupt the study as soon as those cases exceed 10% of the whole cohort.

Intervention assignment and blinding {#Sec8}
------------------------------------

There will be no randomization within this one-armed study design.

To be able to transfer the results to future management concepts (e. g. omitting surgery in cases of VAB -- proven bpCR) the histopathological, study specific evaluation of the VAB specimen will be performed independently of the routine diagnostic evaluation. Nevertheless, the local pathologist will have access to information on pre-NACT histopathological result, cT stage, ycT stage, estrogen receptor status, progesterone receptor status, Her2neu status, grading, and ki-67 status (if available). However, she / he will not receive any information regarding post-NACT surgical specimen results. All pre-surgical variables should be available and included in the pathological evaluation of the VAB specimen after NACT. The interdisciplinary team, including the breast surgeon as well as the patient, will also be blinded to pathological results of the VAB specimen until the final pathological report of the surgical specimen. This will ensure an unbiased surgical intervention.

Pathological work-up of VAB specimens will be performed in analogy to the primary diagnostic setting of suspicious breast lesions \[[@CR26]\]. In order to achieve consistency among pathologists regarding the criteria for evaluation of the VAB specimen, a standard operating procedure will be provided as well as a the possibility of using a reference pathologist's second opinion.

The pathological results of the VAB specimen will be categorized as follows:Category AResidual tumor cells in VAB specimen (= non-bpCR)Category BNo residual tumor cells in the VAB specimen and VAB representative of former tumor region (= bpCR in VAB)Category CNo residual tumor cells in the VAB specimen but VAB unclear representative or not representative of former tumor region (= possible sampling error)

Category C VABs are categorized as uninformative for the primary endpoint of the clinical trial.

The investigators assume that there is no difficulty to diagnose a "Category A" VAB result. The challenging topic is defining a VAB specimen to be pathologically representative of the former tumor region (tumor bed) or not, i. e. to differentiate between "Category B" and "Category C". Only representative VAB samples are informative.

To evaluate intra- and interrater reliability of pathological evaluation of VAB specimen all local pathologists will be asked to send pre-NACT biopsy specimen and post-NACT VAB specimen (H&E sections or virtual microscopy files) of all non-tumorous VABs to the Department of Pathology Heidelberg ("pathological sub-study"). Slides will be digitized, pseudonymized, and returned to different local pathologists. Intra- and interrater reliability evaluation will be performed by at least five pathologists participating in the trial.

Outcomes and measurements {#Sec9}
-------------------------

The primary outcome is the false negative VAB result, i.e. the non-detected residual tumor by VAB compared to breast surgery. We will report this outcome as the false negative rate (FNR = rate of patients with non-detected residual tumor by VAB compared to breast surgery) which is a commonly used and validated measure in diagnostic studies. The FNR will serve as outcome measure in the cohort of the confirmatory primary outcome analysis. It will be calculated as the quotient of the number of cases with bpCR in VAB ("Category B") and residual tumor in surgical specimen (false negative VAB results), divided by the total number of cases with residual tumor in either specimen (VAB and / or surgical specimen). Residual tumor is defined as a positive result, in surgical specimen as well as in VAB.

As our secondary outcomes we will use true negative and true positive results compared to breast surgery. The standard definitions are applied.

Statistical procedures {#Sec10}
----------------------

### Sample size calculation {#Sec11}

As the primary endpoint we use the rate of patients with non-detected residual tumor (=false negative cases), the sample size calculation refers to the required number of patients for which surgery revealed a residual tumor. This number depends on the prevalence of residual tumor in the whole cohort. Motivated by previous works and the definition of the inclusion and exclusion criteria, we assume that this prevalence is at least 0.5. For the test hypotheses the sample size required to achieve a power of 0.8 is given by 238 cases (calculated with the software ADDPLAN Version 6.1.1). Consequently, a total of 476 patients have to be recruited to reach the required number of cases with residual tumor. As the prevalence of 0.5 is only an estimator and, moreover, some patients may be excluded from the analysis because of an unclearly representative VAB, we add an exclusion rate of 0.25 according to the findings in the pilot study \[[@CR25]\]. This results in a total number of 595 patients, which will be rounded up to 600 patients, to be assigned to the trial.

Analysis variables {#Sec12}
------------------

### Derivation of the primary endpoint {#Sec13}

The false negative rate (FNR) will be calculated as the quotient of the number of cases with "pCR in VAB" and residual tumor in surgical specimen (false negative VAB results), divided by the total number of cases with residual tumor in surgical specimen and / or VAB in the cohort of the confirmatory primary outcome analysis (= primary analysis set).

### Derivation of secondary endpoints {#Sec14}

Specificity, negative, and positive predictive values will be calculated according to the standard definitions.

### Primary analysis set {#Sec15}

This data set defines the cohort of patients based on which the primary confirmatory efficacy analysis is performed. The primary analysis set consists of all recruited patients excluding those with a pathologically defined uninformative VAB sample tissue ("Category C": unclear representative or not representative VAB).

### Secondary analysis set {#Sec16}

The Secondary Analysis set consists of all recruited patients including those with an unclear representative or not representative VAB sample tissue in the histopathological assessment. This data set defines the cohort of patients and subsamples based on which the secondary descriptive analyses are performed (see below "Secondary Analysis").

Analysis strategy {#Sec17}
-----------------

### Primary efficacy analysis {#Sec18}

The null hypothesis to be assessed within the confirmatory analysis states that the rate of patients with non-detected residual tumor p is larger or equal to 0.1. Whereas the alternative hypothesis, for which this trial is powered, states that p is at most 0.05. The test hypotheses are thus given by.

H0: *p* ≥ 0.1 versus H1: *p* \< 0.05,

which are tested with the one-sample Binomial-test at a one-sided significance level of α = 0.025.

The rate of patients with non-detected residual tumor p is estimated by the number of cases with diagnosed bpCR in VAB divided by the number of all patients for which surgery or VAB revealed a residual tumor.

### Secondary analyses {#Sec19}

All secondary endpoints are evaluated descriptively for the Primary Analysis Set (all recruited patients excluding "Category C") as well as the Secondary Analysis Set (all recruited patients including "Category C") in order to allow comparability and evaluation of the histopathological analysis. The secondary endpoints will be evaluated for the whole cohort and for six subgroups defined by.the tumor biology (TNBC, HER2+, and HR+/HER2-)the clinical / imaging response assessment (cCR, near cCR, cPR)the assessment of representativeness by specimen radiography.the subjective rating of the physician performing the biopsy.the different hospitals taking part in the study.the guidance method of the minimal invasive biopsy (ultrasound / stereotactic)

The investigators will provide point estimators and corresponding 95% confidence intervals for sensitivity, specificity, and diagnostic odds ratios for bpCR. Predictive values are obtained by using Bayes' theorem based on the different prevalence estimates for bpCR in the full cohort, the subgroups mentioned above, and the trial centers.

The pathological evaluation of the VAB specimen ("pathological sub-study", see above) will be assessed using Cohen's Kappa where satisfactory agreement will be defined as an observed value of \> / = 0.7.

Absolute and relative frequencies of adverse events are provided together with 95% confidence intervals.

We plan to perform an interim data look after having recruited and fully documented 300 participants. Within this interim look, no early testing for efficacy will be performed. However, it will be evaluated if a stop for futility seems indicated. A stop for futility could be indicated if the number of false negative cases is too large to reach the study aim (non-stochastic curtailment) or for other safety reasons.

Discussion {#Sec20}
==========

To date, there are a number of closed, ongoing, and planned trials on this subject, described elsewhere in detail \[[@CR27]\]:

As we do not know the maximum sampling error (= FNR) without impairing loco-regional control rates in case of omitting surgery, we deduced a maximum FNR of 10% from the results of the sentinel node trials. In these studies a false negative rate of 10% did not translate into a worse loco-regional or overall survival \[[@CR28]\]. More recently, the ACOSOG Z0011 trial showed, that leaving lymph node metastases behind in about 20% of the cases, did not translate into worse loco-regional, disease-free and overall survival \[[@CR29]\]. As the cohort of patients treated with NACT is a high risk population we decided for a reasonably low FNR.

During the study we anticipate a set of possible challenges in patient recruitment. First of all, the VAB intervention does not provide participating patients with a personal benefit. By contrast, it involves a second invasive intervention in addition to surgery. We thus assume patients to be reluctant to participate in the study. Hence, a proficient informed consent discussion with the patient and a detailed explanation of the study aim will be crucial for patient recruitment.

Another critical issue in VAB evaluation will be the histopathological evaluation of the representativeness of the VAB specimen. Differentiating accurately between a Category B (= pCR in VAB) and Category C (= possible sampling error) result will be decisive for the achievement of qualified study results. In the pilot study \[[@CR25]\] anticipating this RESPONDER trial, the following stroma and cell reactions were used as criteria based on preceding reports \[[@CR30]--[@CR32]\]. Typical stroma reactions due to NACT included oedematous swelling or fibrosis. Within the fibrotic area a low cell-density was found. Stroma cell reactions were constituted of atypical adenoid cell complexes with large nuclei, regressively transformed residuals of atypical ductal epithelial proliferation, atypical ductal epithelial hyperplasia, or metaplasia of cylindrical cells. Furthermore, cell reactions included macrophage reactions such as the presence of foam cell-like macrophages, giant cells, hemosiderin-charged macrophages, or foam cells indicating resorptive processes. Round cell infiltrates and lympho-histiocytic inflammatory infiltrates were partly present. Based on these findings and experiences histopathological evaluation should allow a standardised diagnostic categorisation.

In case of study results which would permit rejection of the null hypothesis by yielding a false negative rate of less than 10%, VAB would be rated as an accurate diagnostic measure. Possible future trial scenarios would raise difficult questions: In this still hypothetical setting, studies on the therapeutical impact of surgery in bpCR cases would be the consistent consequence. However, the possible setting in which such a study could be realized remains unclear. Ethical and technical issues will have to be addressed for future trial designs. One future option might be a two-armed randomized controlled trial with radiotherapy only as local therapeutic management as one arm and surgery (with or without radiotherapy according to guidelines) as the other arm. Potential endpoints of such a trial might be disease free or in-breast recurrence free survival. Recruitment may be a challenge in a trial offering a non-surgical treatment arm. However, sooner or later the planning of possible future clinical trials on the omission of surgery in bpCR cases will have to be discussed.
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